News Search Results
Nov 03, 2025, 08:30 ET Crystallization Strategies for API Development and Scale-Up, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Nov 03, 2025, 08:30 ET Clinical Signals and Strategic Shifts: Insights That Shape Oncology Drug Development, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Nov 03, 2025, 08:30 ET Lilly plans to build a new €2.6 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Nov 03, 2025, 08:30 ET Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Nov 03, 2025, 08:29 ET Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes
Nov. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases, today announced that it has successfully completed patient
More news about: Virax BioLabs Group Limited
Nov 03, 2025, 08:25 ET NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.
https://newcelx.com/investors-media/investors/corporate-presentation/. About NewcelXNewcelX Ltd. (NASDAQ: NCEL) is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated
More news about: NewcelX Ltd.
Nov 03, 2025, 08:05 ET INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults
PLYMOUTH MEETING, Pa., Nov. 3, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Nov 03, 2025, 08:00 ET Matica Bio, a CDMO Leader in Oncolytic Virus Manufacturing, Partners with Calidi Biotherapeutics to Advance Calidi's Project Toward IND
preferred partner for innovative CGT developers worldwide. About Matica Biotechnology, Inc. Matica Biotechnology is a viral vector Contract Development and Manufacturing Organization (CDMO) that leverages advanced technologies at
More news about: Matica Biotechnology, Inc.
Nov 03, 2025, 08:00 ET Syantra and Alamo Breast Cancer Foundation launch first-of-its-kind partnership
CALGARY, AB, Nov. 3, 2025 /PRNewswire/ - Syantra, Inc., a biotechnology company revolutionizing cancer detection, and Alamo Breast Cancer Foundation (ABCF), a nonprofit dedicated to the prevention/cure of breast cancer,
More news about: Syantra Inc.
Nov 03, 2025, 08:00 ET Ginkgo Bioworks Awarded Project Agreement through BARDA's BioMaP-Consortium
neuimmune.com. About ProteoNic ProteoNic is a privately held biotechnology company with offices in Leiden, The Netherlands. The company specializes in advanced cell line generation and viral vector production, with a focus
More news about: Ginkgo Bioworks
Nov 03, 2025, 07:00 ET ScaleReady Announces a G-Rex® Grant has been awarded to Sonoma Biotherapeutics
time. About Sonoma Biotherapeutics Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases by restoring immune system
More news about: Bio-Techne Corporation
Oct 31, 2025, 17:20 ET MoonLake Immunotherapeutics Class Action: MLTX Stockholders Should Contact Robbins LLP for Information About the Class Action Against
Company: MoonLake Immunotherapeutics (MLTX) is a Swiss clinical-stage biotechnology company focused on inflammatory diseases driven by interleukin-17 (IL-17), particularly in dermatology and rheumatology.
More news about: Robbins LLP
Oct 31, 2025, 16:53 ET INOVIO Reports Inducement Grant Under Inducement Plan
PLYMOUTH MEETING, Pa., Oct. 31, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Oct 31, 2025, 16:01 ET AMGEN ANNOUNCES 2025 FOURTH QUARTER DIVIDEND
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Oct 31, 2025, 13:51 ET Carl June, Bruce Levine, Isabelle Rivière, and Michel Sadelain receive the 2025 Merkin Prize at the Broad Institute for chimeric antigen receptor (CAR) T-cell therapy
from MIT, Harvard, Harvard's primary teaching hospitals, other academic institutions, and leading corporate partners in the pharmaceutical and biotechnology industries, all of whom share the goal of translating research findings into safe and effective therapeutic interventions for all common and rare
More news about: Broad Institute
Oct 31, 2025, 11:50 ET The Galien Foundation Honors Michael J. Fox and 2025 Prix Galien Award Recipients
subcommittee members, and 15 advisory board members, including three Nobel Laureates—honored the 2025 Prix Galien Award winners in the categories of Best Biotechnology Product, Best Pharmaceutical Product, Best Product for Rare/Orphan Diseases, Best Medical Technology, Best Digital Health Solution, Incubators/Accelerators/Equity,
More news about: The Galien Foundation
Oct 31, 2025, 09:30 ET Visionary Holdings Inc. 2025 Annual General Meeting Concludes Successfully: Completes Board Renewal, Anchors New Direction for Compliant Development
such as corporate management, financial management, legal compliance, international education, high-end medical aesthetics and big health, and biotechnology. Based on the statistics from the dual voting mode of "on-site voting + email voting", 9 candidates – Mr. William T. Chai,
More news about: Visionary Holdings Inc.
Oct 31, 2025, 09:00 ET AMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Oct 31, 2025, 08:00 ET Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock
Oct. 31, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system
More news about: Intensity Therapeutics Inc.
Oct 31, 2025, 08:00 ET Servier's VORANIGO® (vorasidenib) Receives Prestigious 2025 Prix Galien USA Award
the most critical products introduced in the public market and acknowledges the achievements of the best research teams in the pharmaceutical, biotechnology, medical technology, and digital health industries. The Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.
More news about: Servier Pharmaceuticals
Oct 31, 2025, 07:00 ET Marengo to Present Late-Breaking Clinical Oral Abstract at SITC 2025 Highlighting Initial Monotherapy Activity of Invikafusp Alfa in Tissue-Agnostic, TMB-High Advanced Cancers
CAMBRIDGE, Mass., Oct. 31, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology and inflammation & immunology (I&I), today announced that it
More news about: Marengo Therapeutics
Oct 31, 2025, 06:30 ET Agriculture Biotechnology Market worth $144.25 billion by 2030- Exclusive Report by MarketsandMarkets™
Plant and microbial biotechnology to hold significant share during forecast period. The plant biotechnology and microbial biotechnology segments are expected to hold a significant share of the agriculture biotechnology market during the forecast
More news about: MarketsandMarkets
Oct 30, 2025, 21:08 ET Stockholder Alert: Robbins LLP Informs Investors of the Avantor, Inc. Class Action Lawsuit
AVTR) common stock between March 5, 2024 and October 28, 2025. Avantor provides scientific products and services for customers in biotechnology, pharmaceuticals, healthcare, education, government, and other industries.
More news about: Robbins LLP
Oct 30, 2025, 18:00 ET Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
Oct 30, 2025, 17:30 ET Revenue Cycle Management (RCM) Market to Grow at 45.95% CAGR, Surpassing USD 28560 Billion by 2035 | Vantage Market Research
market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize
More news about: Vantage Market Research